阿帕替尼联合消岩汤治疗晚期非鳞非小细胞肺癌临床疗效观察

  目的  研究观察甲磺酸阿帕替尼片联合消岩汤治疗晚期非鳞非小细胞肺癌（non-small cell lung cancer，NSCLC）的临床疗效。  方法  选取晚期非鳞NSCLC患者38例，随机分为阿帕替尼治疗组18例（A组），阿帕替尼联合消岩汤加减方治疗组20例（B组），二组治疗期间均未行手术及放、化疗。  结果  晚期非鳞NSCLC患者服用阿帕替尼后中位无进展生存期（median progression free survival，mPFS）可达3个月，阿帕替尼联合消岩汤组mPFS、客观缓解率（objective response rate，ORR）及疾病控制率（disease control rate，DCR）较阿帕替尼单药组差异无统计学意义（P>0.05）；在改善临床症状及不良反应方面，阿帕替尼联合消岩汤组均优于阿帕替尼单药组（P < 0.05）。  结论  阿帕替尼联合消岩汤加减方治疗晚期非鳞NSCLC可改善患者临床症状，并降低不良反应的发生率。 

Clinical research on apatinib combined with Xiaoyan decoction for the treatment of non-squamous non-small cell lung cancer

Objective:To determine the effect of apatinib combined with Xiaoyan decoction for the treatment of non-squamous non-small cell lung cancer. Methods:Thirty-eight patients with non-squamous non-small cell lung cancer were randomly categorized into apatinib group (group A, 18 cases) and apatinib combined with Xiaoyan decoction group (group B, 20 cases). All patients did not under-go surgical treatment, radiotherapy, or chemotherapy during the study. Results:The median progression free survival (mPFS) of ad-vanced non-squamous non-small cell lung cancer patients reached up to 3 months. The mPFS, objective response rate, and disease control rate of the apatinib combined with Xiaoyan decoction group showed no significant difference and statistical significance (P>0.05). The apatinib combined with Xiaoyan decoction group was superior to the apatinib group with regard to alleviating clinical symp-toms and adverse reactions (P<0.05). Conclusion:Xiaoyan decoction combined with apatinib can improve the clinical symptoms of pa-tients and reduce the incidence of adverse reactions in the treatment of advanced non-squamous non-small cell lung cancer.